Targeting angiogenesis in childhood sarcomas

Peter J Houghton, Hemant K. Bid

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.

Original languageEnglish (US)
Article number601514
JournalSarcoma
Volume2011
DOIs
StatePublished - Feb 1 2011
Externally publishedYes

Fingerprint

Sarcoma
Neoplasms
Blood Vessels
Pediatrics
Angiogenesis Inhibitors
Cytostatic Agents
Clinical Trials
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Targeting angiogenesis in childhood sarcomas. / Houghton, Peter J; Bid, Hemant K.

In: Sarcoma, Vol. 2011, 601514, 01.02.2011.

Research output: Contribution to journalReview article

@article{6b603214e52341ceb859c0bedb5fe124,
title = "Targeting angiogenesis in childhood sarcomas",
abstract = "Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.",
author = "Houghton, {Peter J} and Bid, {Hemant K.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1155/2011/601514",
language = "English (US)",
volume = "2011",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Targeting angiogenesis in childhood sarcomas

AU - Houghton, Peter J

AU - Bid, Hemant K.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.

AB - Angiogenesis and vasculogenesis constitute two processes in the formation of new blood vessels and are essential for progression of solid tumors. Consequently, targeting angiogenesis, and to a lesser extent vasculogenesis, has become a major focus in cancer drug development. Angiogenesis inhibitors are now being tested in pediatric populations whereas inhibitors of vasculogenesis are in an earlier stage of development. Despite the initial enthusiasm for targeting angiogenesis for treatment of cancer, clinical trials have shown only incremental increases in survival, and agents have been largely cytostatic rather than inducing tumor regressions. Consequently, the role of such therapeutic approaches in the context of curative intent for childhood sarcomas is less clear. Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers.

UR - http://www.scopus.com/inward/record.url?scp=79251589906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251589906&partnerID=8YFLogxK

U2 - 10.1155/2011/601514

DO - 10.1155/2011/601514

M3 - Review article

C2 - 21197468

AN - SCOPUS:79251589906

VL - 2011

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 601514

ER -